Insider Selling: Inari Medical, Inc. (NASDAQ:NARI) Director Sells 60,000 Shares of Stock

Inari Medical, Inc. (NASDAQ:NARI) Director William Hoffman sold 60,000 shares of Inari Medical stock in a transaction on Monday, November 18th. The stock was sold at an average price of $51.16, for a total value of $3,069,600.00. Following the sale, the director now owns 501,233 shares in the company, valued at $25,643,080.28. The trade was a 10.69 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

William Hoffman also recently made the following trade(s):

• On Tuesday, October 29th, William Hoffman sold 40,000 shares of Inari Medical stock. The stock was sold at an average price of $50.05, for a total transaction of $2,002,000.00.
• On Wednesday, October 16th, William Hoffman sold 40,000 shares of Inari Medical stock. The shares were sold at an average price of $45.02, for a total transaction of $1,800,800.00.
• On Monday, September 16th, William Hoffman sold 40,000 shares of Inari Medical stock. The stock was sold at an average price of $45.83, for a total transaction of $1,833,200.00.

Inari Medical Trading Down 3.9 %

NASDAQ NARI opened at $49.00 on Thursday. Inari Medical, Inc. has a 1 year low of $36.73 and a 1 year high of $67.13. The company’s 50 day simple moving average is $45.52 and its two-hundred day simple moving average is $47.19.

Hedge Funds Weigh In On Inari Medical

A number of institutional investors have recently added to or reduced their stakes in the business. Vestal Point Capital LP grew its holdings in shares of Inari Medical by 342.9% during the third quarter. Vestal Point Capital LP now owns 1,550,000 shares of the company’s stock worth $63,922,000 after purchasing an additional 1,200,000 shares in the last quarter. Point72 Asset Management L.P. lifted its position in Inari Medical by 113.3% during the second quarter. Point72 Asset Management L.P. now owns 1,481,283 shares of the company’s stock valued at $71,324,000 after purchasing an additional 786,691 shares during the last quarter. Armistice Capital LLC grew its stake in Inari Medical by 353.1% in the 2nd quarter. Armistice Capital LLC now owns 1,009,252 shares of the company’s stock worth $48,595,000 after buying an additional 786,501 shares in the last quarter. Jennison Associates LLC increased its holdings in shares of Inari Medical by 63.2% in the 3rd quarter. Jennison Associates LLC now owns 1,576,641 shares of the company’s stock worth $65,021,000 after buying an additional 610,468 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Inari Medical by 11.1% during the 1st quarter. Vanguard Group Inc. now owns 5,599,854 shares of the company’s stock valued at $268,681,000 after buying an additional 561,562 shares in the last quarter. 90.98% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

NARI has been the subject of a number of recent research reports. Canaccord Genuity Group raised their target price on Inari Medical from $71.00 to $74.00 and gave the stock a “buy” rating in a research report on Tuesday, October 29th. Leerink Partners started coverage on Inari Medical in a report on Tuesday, September 3rd. They issued a “market perform” rating and a $47.00 price objective for the company. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Inari Medical in a report on Friday, August 9th. They set a “buy” rating and a $68.00 price objective on the stock. Wells Fargo & Company reduced their target price on shares of Inari Medical from $84.00 to $65.00 and set an “overweight” rating for the company in a research note on Wednesday, July 31st. Finally, Robert W. Baird upped their price target on shares of Inari Medical from $66.00 to $67.00 and gave the company an “outperform” rating in a research note on Tuesday, October 29th. Six equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Inari Medical currently has an average rating of “Hold” and an average target price of $58.89.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.